BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Szpakowska M, Nevins AM, Meyrath M, Rhainds D, D'huys T, Guité-Vinet F, Dupuis N, Gauthier PA, Counson M, Kleist A, St-Onge G, Hanson J, Schols D, Volkman BF, Heveker N, Chevigné A. Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3. Br J Pharmacol 2018;175:1419-38. [PMID: 29272550 DOI: 10.1111/bph.14132] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Bayrak A, Mohr F, Kolb K, Szpakowska M, Shevchenko E, Dicenta V, Rohlfing AK, Kudolo M, Pantsar T, Günther M, Kaczor AA, Poso A, Chevigné A, Pillaiyar T, Gawaz M, Laufer SA. Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation. J Med Chem 2022. [PMID: 36150079 DOI: 10.1021/acs.jmedchem.2c01198] [Reference Citation Analysis]
2 Gout DY, Groen LS, van Egmond M. The present and future of immunocytokines for cancer treatment. Cell Mol Life Sci 2022;79:509. [PMID: 36066630 DOI: 10.1007/s00018-022-04514-9] [Reference Citation Analysis]
3 Yen Y, Schafer CT, Gustavsson M, Eberle SA, Dominik PK, Deneka D, Zhang P, Schall TJ, Kossiakoff AA, Tesmer JJG, Handel TM. Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias. Sci Adv 2022;8:eabn8063. [DOI: 10.1126/sciadv.abn8063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Kleist AB, Jenjak S, Sente A, Laskowski LJ, Szpakowska M, Calkins MM, Anderson EI, Mcnally LM, Heukers R, Bobkov V, Peterson FC, Thomas MA, Chevigné A, Smit MJ, Mccorvy JD, Babu MM, Volkman BF. Conformational selection guides β-arrestin recruitment at a biased G protein–coupled receptor. Science 2022;377:222-8. [DOI: 10.1126/science.abj4922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 D'Uonnolo G, Reynders N, Meyrath M, Abboud D, Uchański T, Laeremans T, Volkman BF, Janji B, Hanson J, Szpakowska M, Chevigné A. The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-B. Front Immunol 2022;13:868579. [PMID: 35720349 DOI: 10.3389/fimmu.2022.868579] [Reference Citation Analysis]
6 Eberle SA, Gustavsson M. A Scintillation Proximity Assay for Real-Time Kinetic Analysis of Chemokine–Chemokine Receptor Interactions. Cells 2022;11:1317. [DOI: 10.3390/cells11081317] [Reference Citation Analysis]
7 Simmons SJ, Oliver CF, McCloskey NS, Reitz AB, Nayak SU, Watson MN, Rawls SM. Paradoxical anxiolytic effect of the 'bath salt' synthetic cathinone MDPV during early abstinence is inhibited by a chemokine CXCR4 or CCR5 receptor antagonist. Drug Alcohol Depend 2022;230:109204. [PMID: 34871976 DOI: 10.1016/j.drugalcdep.2021.109204] [Reference Citation Analysis]
8 Palmer CB, Meyrath M, Canals M, Kostenis E, Chevigné A, Szpakowska M. Atypical opioid receptors: unconventional biology and therapeutic opportunities. Pharmacol Ther 2021;:108014. [PMID: 34624426 DOI: 10.1016/j.pharmthera.2021.108014] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Passman AM, Strauss RP, McSpadden SB, Finch-Edmondson M, Andrewartha N, Woo KH, Diepeveen LA, Zhao W, Fernández-Irigoyen J, Santamaría E, Medina-Ruiz L, Szpakowska M, Chevigné A, Park H, Carlessi R, Tirnitz-Parker JEE, Blanco JR, London R, Callus BA, Elsegood CL, Baker MV, Martínez A, Yeoh GCT, Ochoa-Callejero L. Maraviroc Prevents HCC Development by Suppressing Macrophages and the Liver Progenitor Cell Response in a Murine Chronic Liver Disease Model. Cancers (Basel) 2021;13:4935. [PMID: 34638423 DOI: 10.3390/cancers13194935] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Lai WY, Mueller A. Latest update on chemokine receptors as therapeutic targets. Biochem Soc Trans 2021;49:1385-95. [PMID: 34060588 DOI: 10.1042/BST20201114] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Grafinger KE, Vandeputte MM, Cannaert A, Ametovski A, Sparkes E, Cairns E, Juchli PO, Haschimi B, Pulver B, Banister SD, Stove CP, Auwärter V. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays. Drug Test Anal 2021;13:1412-29. [PMID: 33908179 DOI: 10.1002/dta.3054] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
12 Meyrath M, Palmer CB, Reynders N, Vanderplasschen A, Ollert M, Bouvier M, Szpakowska M, Chevigné A. Proadrenomedullin N-Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3/CXCR7. ACS Pharmacol Transl Sci 2021;4:813-23. [PMID: 33860204 DOI: 10.1021/acsptsci.1c00006] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
13 Chevigné A, Janji B, Meyrath M, Reynders N, D'Uonnolo G, Uchański T, Xiao M, Berchem G, Ollert M, Kwon YJ, Noman MZ, Szpakowska M. CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6. Cancers (Basel) 2021;13:1054. [PMID: 33801414 DOI: 10.3390/cancers13051054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
14 Ishizuka M, Harada M, Nomura S, Ko T, Ikeda Y, Guo J, Bujo S, Yanagisawa-Murakami H, Satoh M, Yamada S, Kumagai H, Motozawa Y, Hara H, Fujiwara T, Sato T, Takeda N, Takeda N, Otsu K, Morita H, Toko H, Komuro I. CXCR7 ameliorates myocardial infarction as a β-arrestin-biased receptor. Sci Rep 2021;11:3426. [PMID: 33564089 DOI: 10.1038/s41598-021-83022-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Eiger DS, Boldizsar N, Honeycutt CC, Gardner J, Rajagopal S. Biased agonism at chemokine receptors. Cell Signal 2021;78:109862. [PMID: 33249087 DOI: 10.1016/j.cellsig.2020.109862] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
16 Kouzeli A, Collins PJ, Metzemaekers M, Meyrath M, Szpakowska M, Artinger M, Struyf S, Proost P, Chevigne A, Legler DF, Eberl M, Moser B. CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems. Front Immunol 2020;11:561404. [PMID: 33123134 DOI: 10.3389/fimmu.2020.561404] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
17 Meyrath M, Reynders N, Uchański T, Chevigné A, Szpakowska M. Systematic reassessment of chemokine-receptor pairings confirms CCL20 but not CXCL13 and extends the spectrum of ACKR4 agonists to CCL22. J Leukoc Biol 2021;109:373-6. [PMID: 32480426 DOI: 10.1002/JLB.2AB0520-275R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jaracz-Ros A, Bernadat G, Cutolo P, Gallego C, Gustavsson M, Cecon E, Baleux F, Kufareva I, Handel TM, Bachelerie F, Levoye A. Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors. J Leukoc Biol 2020;107:1123-35. [PMID: 32374043 DOI: 10.1002/JLB.2MA0320-383RR] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Moussouras NA, Hjortø GM, Peterson FC, Szpakowska M, Chevigné A, Rosenkilde MM, Volkman BF, Dwinell MB. Structural Features of an Extended C-Terminal Tail Modulate the Function of the Chemokine CCL21. Biochemistry 2020;59:1338-50. [PMID: 32182428 DOI: 10.1021/acs.biochem.0c00047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
20 Gustavsson M. New insights into the structure and function of chemokine receptor:chemokine complexes from an experimental perspective. J Leukoc Biol 2020;107:1115-22. [DOI: 10.1002/jlb.2mr1219-288r] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
21 Wouters E, Walraed J, Robertson MJ, Meyrath M, Szpakowska M, Chevigné A, Skiniotis G, Stove C. Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds. ACS Pharmacol Transl Sci 2020;3:285-95. [PMID: 32296768 DOI: 10.1021/acsptsci.9b00069] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
22 Quinn KE, Mackie DI, Caron KM. Emerging roles of atypical chemokine receptor 3 (ACKR3) in normal development and physiology. Cytokine 2018;109:17-23. [PMID: 29903572 DOI: 10.1016/j.cyto.2018.02.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 6.7] [Reference Citation Analysis]
23 Adlere I, Caspar B, Arimont M, Dekkers S, Visser K, Stuijt J, de Graaf C, Stocks M, Kellam B, Briddon S, Wijtmans M, de Esch I, Hill S, Leurs R. Modulators of CXCR4 and CXCR7/ACKR3 Function. Mol Pharmacol 2019;96:737-52. [DOI: 10.1124/mol.119.117663] [Cited by in Crossref: 21] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
24 Gustavsson M, Dyer DP, Zhao C, Handel TM. Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding. Sci Signal 2019;12:eaaw3657. [PMID: 31506383 DOI: 10.1126/scisignal.aaw3657] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
25 Neirinckx V, Hau AC, Schuster A, Fritah S, Tiemann K, Klein E, Nazarov PV, Matagne A, Szpakowska M, Meyrath M, Chevigné A, Schmidt MHH, Niclou SP. The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma. Neurooncol Adv 2019;1:vdz024. [PMID: 32642659 DOI: 10.1093/noajnl/vdz024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Reynders N, Abboud D, Baragli A, Noman MZ, Rogister B, Niclou SP, Heveker N, Janji B, Hanson J, Szpakowska M, Chevigné A. The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment. Cells 2019;8:E613. [PMID: 31216755 DOI: 10.3390/cells8060613] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
27 Koenen J, Bachelerie F, Balabanian K, Schlecht-Louf G, Gallego C. Atypical Chemokine Receptor 3 (ACKR3): A Comprehensive Overview of its Expression and Potential Roles in the Immune System. Mol Pharmacol 2019;96:809-18. [PMID: 31040166 DOI: 10.1124/mol.118.115329] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
28 Dale NC, Johnstone EKM, White CW, Pfleger KDG. NanoBRET: The Bright Future of Proximity-Based Assays. Front Bioeng Biotechnol 2019;7:56. [PMID: 30972335 DOI: 10.3389/fbioe.2019.00056] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
29 Elmansi AM, Awad ME, Eisa NH, Kondrikov D, Hussein KA, Aguilar-Pérez A, Herberg S, Periyasamy-Thandavan S, Fulzele S, Hamrick MW, McGee-Lawrence ME, Isales CM, Volkman BF, Hill WD. What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands.Pharmacol Ther. 2019;198:90-108. [PMID: 30759373 DOI: 10.1016/j.pharmthera.2019.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
30 Laschet C, Dupuis N, Hanson J. A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCR-G protein interactions. J Biol Chem 2019;294:4079-90. [PMID: 30593506 DOI: 10.1074/jbc.RA118.006231] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
31 Szpakowska M, Nevins AM, Meyrath M, Rhainds D, D'huys T, Guité-Vinet F, Dupuis N, Gauthier PA, Counson M, Kleist A, St-Onge G, Hanson J, Schols D, Volkman BF, Heveker N, Chevigné A. Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3. Br J Pharmacol 2018;175:1419-38. [PMID: 29272550 DOI: 10.1111/bph.14132] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 6.5] [Reference Citation Analysis]